Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Large Volume Increase – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw an uptick in trading volume on Thursday. Approximately 328,839 shares were traded during trading, an increase of 34% from the previous session’s volume of 246,080 shares. The stock last traded at $19.0580 and had previously closed at $19.31.

Analysts Set New Price Targets

CHGCY has been the topic of a number of research analyst reports. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Nomura raised Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. Finally, UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Performance

The stock’s 50 day simple moving average is $21.18 and its two-hundred day simple moving average is $23.46. The firm has a market capitalization of $62.64 billion, a PE ratio of 20.68 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%.The company had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.38 billion. Equities research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its research focuses on oncology, immunology, neuroscience, hematology and other areas of significant unmet medical need, with capabilities spanning drug discovery, clinical development, manufacturing and commercialization.

Chugai’s portfolio includes medicines such as Actemra (tocilizumab), an immunology treatment; Hemlibra (emicizumab), used to prevent bleeding in people with hemophilia A; and Alecensa (alectinib), a targeted therapy for certain forms of lung cancer.